The Cholesterol Conspiracy Podcast by Ladd McNamara, M.D. » Heart Disease http://www.cholesterolconspiracy.com Ladd McNamara M.D. Reveals the Truth About Statins and Cholestorol Thu, 18 Feb 2010 18:04:52 +0000 http://wordpress.org/?v=2.8.5 en hourly 1 Ladd McNamara M.D. Reveals the Truth About Statins and Cholestorol The Cholesterol Conspiracy Podcast by Ladd McNamara, M.D. no 2008 - Total Wellness Network Ladd McNamara M.D. Reveals the Truth About Statins and Cholestorol The Cholesterol Conspiracy Podcast by Ladd McNamara, M.D. » Heart Disease http://www.cholesterolconspiracy.net/graphics/album_144-144_v01.jpg http://www.cholesterolconspiracy.com Episode 17: High Cholesterol and Low Testosterone http://www.cholesterolconspiracy.com/episode-17-high-cholesterol-and-low-testosterone/ http://www.cholesterolconspiracy.com/episode-17-high-cholesterol-and-low-testosterone/#comments Tue, 08 Dec 2009 04:23:24 +0000 laddmcnamara http://www.cholesterolconspiracy.com/?p=80 In this episode Dr. Ladd McNamara answers the apparent dilemma "I’m on Antioxidants, But My Cholesterol is Still High!" and discusses how low free testosterone levels in men are associated with an increased risk of heart disease.

  • Chapter 34: "I’m on Antioxidants, But My Cholesterol is Still High!"
  • Chapter 35: Age and Arterial Calcifications
  • Chapter 36: Low Free Testosterone Levels in Men are Associated with an Increased Risk of Heart Disease

Chapter Excerpts

I knew it would be better if she had a lower LDL cholesterol level and took antioxidants, but I agreed with her about not going on the cholesterol-lowering drug.
…To her relief, her level of oxidized LDL cholesterol was much lower than what is considered normal. It was better than “good.” Her percentage of oxidized LDL cholesterol was so low it amazed even me. Brenda was set free from the Cholesterol Conspiracy.

Calcium and magnesium imbalances lead to osteoporosis and calcium deposits in the arteries.

In a recent study in men’s health, doctors measuring the degree of coronary artery disease, diagnosed with angioplasty, found that even more important than cholesterol, diabetes, smoking, high blood pressure, and obesity, the major predictors for the severity of atherosclerosis turned out to be age, low levels of HDL cholesterol, and low levels of free testosterone.

Ladd McNamara, M.D.

Chapter References

  • 163: Chandalia M, Garg A, Lutjohann D, von Bergmann K, Grundy SM, Brinkley LJ. Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N Engl J Med. 2000 May;342(19):1392-8.
  • 163: Lawrence F. Bielak, John A. Rumberger, Patrick F. Sheedy, II, Robert S. Schwartz, and Patricia A. Peyser. Probabilistic model for prediction of angiographically defined obstructive coronary artery disease using electron beam computed tomography calcium score strata. Circulation 2000 102: 380-385.
  • 164: O’Rourke R, Brundage B, Froelicher V, et al. American College of Cardiology/American Heart Association Expert Consensus Document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. J Amer Coll Cardiol 2000 36(1):326-340.
  • 165: Howe A, Webster W. Warfarin exposure and calcification of the arterial system in the rat. Int J Exp Pathol 2000 Feb;81(1):51-56.
  • 166: Vermeer C, Schurgers L. A comprehensive review of vitamin K and vitamin K antagonists. Hematol Oncol Clin North Am 2000 Apr;14(2):339-353.
  • 167: Phillips GB, Pinkernell BH, Jing TY. Are major risk factors for myocardial infarction the major predictors of degree of coronary artery disease in men? Metabolism 2004 Mar;53(3):324-329.
  • 168: Dobrizycki S, Serwatka W, Nadlewski S, et al. An assessment of correlation between endogenous sex hormone levels and the extensiveness of coronary heart disease and the ejection fraction of the left ventricle in males. J Med Invest. 2003 Aug;50(3-4):162-169.
  • 169: Muller M, van den Beld AW, Bots ML, Grobbee DE, Lamberts SW, van der Schouw YT. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation 2004 May 4;109(17):2074-79.
  • 170: Dzugan SA, Smith RA. Hypercholesterolemia treatment: a new hypothesis or just an accident? Med Hypothesis. 2002 Dec;59(6):751-6.
  • 171: Dzugan SA, Smith RA. Broad spectrum restoration in natural steroid hormones as possible treatment for hypercholesterolemia. Bull Urg Rec Med. 2002;3(2):278-284.
  • 172: Chen C, et al. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the carotene and retinal efficacy trial. Cancer Epidimeiol Biomarkers Prev. 2003 Dec;12(12):1410-1416.
  • 173: Stattin P, Lumme S, Tenkanen L, et al. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer. 2004 Jan 20;108(3):418-424.
  • 174: Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypgonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol. 2003 Dec;170(6 Pt 1):2348-2351.
  • 175: Raivio T, Santti H, Schatzl G, et al. Reduced circulating androgen bioactivity in patients with prostate cancer. Prostate. 2003 May 15;55(3):194-198.

Ladd McNamara, M.D.

]]> http://www.cholesterolconspiracy.com/episode-17-high-cholesterol-and-low-testosterone/feed/ 0 Antioxidants,Atherosclerosis,Cholesterol Conspiracy,Heart Disease,High Cholesterol,Ladd McNamara,Low Testosterone,Osteoporosis In this episode Dr. Ladd McNamara answers the apparent dilemma "I’m on Antioxidants, But My Cholesterol is Still High!" and discusses how low free testosterone levels in men are associated with an increased risk of heart disease. In this episode Dr. Ladd McNamara answers the apparent dilemma "I’m on Antioxidants, But My Cholesterol is Still High!" and discusses how low free testosterone levels in men are associated with an increased risk of heart disease. Chapter ... The Cholesterol Conspiracy Podcast by Ladd McNamara, M.D. no 16:03 Episode 16: The “Best” Way to Reduce the Risk of Cardiac Death: Part 3 (According to Dr. Ladd McNamara) http://www.cholesterolconspiracy.com/episode-16-the-real-and-alternative-way-to-reduce-the-risk-of-death-from-heart-disease-and-stroke-part-3/ http://www.cholesterolconspiracy.com/episode-16-the-real-and-alternative-way-to-reduce-the-risk-of-death-from-heart-disease-and-stroke-part-3/#comments Tue, 01 Dec 2009 04:19:49 +0000 laddmcnamara http://www.cholesterolconspiracy.com/?p=78 In this episode Dr. Ladd McNamara discusses vitamins, minerals, antioxidants, and essential fatty acids: a real an alternative way to reduce the risk of death from heart disease and stroke.

  • Chapter 33: Vitamins, Minerals, Antioxidants, and Essential Fatty Acids: The Real Way to Reduce the Risk of Death from Heart Disease and Stroke – Part 3

Chapter Excerpts

Alpha-Lipoic Acid works in many ways to protect against disease and maintain health. ALA protects LDL cholesterol from oxidation, reduces the inflammatory reaction of the arteries, along with magnesium helps to maintain a health blood pressure. Alpha-Lipoic Acid works together with co-enzyme Q10 in the metabolism of sugar into energy.

Olive Oil and Olive Oil Extracts contain polyphenol antioxidants that are in part responsible for the benefits of the Mediterranean diet. Studies have shown those who consume more of these antioxidant compounds have a greatly reduced risk of heart disease and cancer, let alone a prolongation of life.

Fish oil supplements (containing DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid) have been shown to decrease the risk of cardiac death greater than the use of statin drugs, …and without any toxic side-effects. Thus, more evidence of the Cholesterol Conspiracy.

In addition to magnesium supplementation, researchers are finding promise in the higher rates of survival after heart attacks when high-dose antioxidants are commenced shortly after such an attack.

Diets high in both soluble and insoluble fiber help reduce blood lipid levels, cholesterol, and insulin intolerance.

Ladd McNamara, M.D.

Chapter References

  • 130: Zhang WJ, Frei B. Alpha-lipoic acid inhibits TNF-alpha-induced NFkappa B activation and adhesion molecule expression in human aortic endothelial cells. FASEB J 2001 Nov;15(13):2423-2432.
  • 131: El Midaoui A, de Champlain J. Prevention of hypertension, insulin resistance, and oxidative stress by alpha-lipoic acid. Hypertension 2002 Feb;39(2):303-307.
  • 132: Takaoka M, et al. Effects of alpha-lipoic acid on deoxycorticos-terone acetate-salt-induced hypertension in rats. Eur J Pharmacol 2001 Jul;20;424(2):121-129.
  • 133: Koufaki M, et al. Novel potent inhibitors of lipid peroxidation with protective effects against reperfusion arrhythmias. J Med Chem 2001 Nov 22;44(24):4300-4303.
  • 134: Gonzalez-Perez O, Gonzalez-Castaneda R, Huerta M, et al. Beneficial effects of -lipoic acid plus vitamin E on neurological deficit, reactive gliosis and neuronal remodeling in the penumbra of the ischemic rat brain. Neuroscience Letters, 2002 March 15, 321(5);1:100-104.
  • 135: Chen C et al. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the carotene and retinal efficacy trial. Cancer Epidimeiol Biomarkers Prev. 2003 Dec;12(12):1410-1416.
  • 136: Upritchard J, Suterhland W, Mann J. Effect of supplementation with tomato juice, vitamin E, and vitamin C oxidation and products of inflammatory activity in type 2 diabetes. Diabetes Care. 2000 Jun;23(6):733-738.
  • 137: Decker E, et al. Inhibition of low-density lipoprotein oxidation by carnosine histidine. J Agric Food Chem 2001 Jan;49(1):511-516.
  • 138: Owen RW, et al. Olive oil consumption and health: the possible role of antioxidants. Lancet Oncol, 2000, Oct., 1:107-12.
  • 139: Visioli F, et al. Antioxidant and other biological activities of phenols from olives and olive oil. Med Res Rev. 2002 Jan;22(1):65-75.
  • 140: Simopoulos Ap. The traditional diet of Greece and cancer. Eur J Cancer Prev. 2004 Jun;13(3):219-30.
  • 141: Visioli F., et al. Low density lipoprotein oxidation is inhibited in vitro by olive oil constituents. Atherosclerosis. 1995 Sep;117(1):25-32.
  • 142: Cullinen K. Olive oil in the treatment of hypercholesterolemia. Med Health R.I. 2006 Mar;89(3):113.
  • 143: Nagyova A, et al. Effects of dietary extra virgin olive oil on serum lipid resistance to oxidation and fatty acid composition in elderly lipidemic patients. Bratisl Lek Listy. 2003;104(7-8):218-21.
  • 144: Martinez-Gonzalez MA. The SUN cohort study (Seguimiento University of Navarra). Public Health Nutr. 2006 Feb;9(1A):127-31.
  • 145: Bogani P., et al. Postprandial anti-inflammatory and antioxidant effects of extra virgin olive oil. Atherosclerosis. 2006 Feb 17; [Epub ahead of print].
  • 146: Fito M., et al. Antioxidant effect of virgin olive oil in patients with stable coronary heart disease: a randomized, crossover, controlled, clinical trial. Atherosclerosis. 2005 Jul;181(1):149-58.
  • 147: Fernandez-Jarne E., et al. Risk of first non-fatal myocardial infarction negatively associated with olive oil consumption: a case-control study in Spain. Int J Epidemiol. 2002, Apr;31(2):474-80.
  • 148: Visioli F., Galli C. Antiatherogenic components of olive oil. Curr Atheroscler Rep. 2001. Jan;3(1):64-7.
  • 149: Visioli F., et al. Low density lipoprotein oxidation is inhibited in vitro by olive oil constituents. Atherosclerosis. 1995 Sep;117(1):25-32.
  • 150: Nestel P, et al. The n-3 fatty acids eiosapentaenoid acid and docosahexaenoic acid increase systemic arterial compliance in humans. Am J Clin Nutr 2002 Aug;76(2):326-330.
  • 151: McLennan O. Myocardial membrane fatty acids and the antiarrhythmic actions of dietary fish oil in animal models. Lipids 2001 36 Suppl: S111-S114.
  • 152: Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italian per lo Studio dells Soprvvivenza nell’Infarto Micardico (GISSI)-Prevenzione. Circulation. 2002 Apr 23;105:1897-1903.
  • 56: Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis. 2004. Mar;173(1):1-12.
  • 57: Tsimikas S, et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation. 2004 Sep 14;110(11):1406-12.
  • 152: Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italian per lo Studio dells Soprvvivenza nell’Infarto Micardico (GISSI)-Prevenzione. Circulation. 2002 Apr 23;105:1897-1903.
  • 154: Bernier M, et al. Reperfusion-induced arrhythmias and oxygen-derived free radicals. Circulation Res. 1986 58:331-340.
  • 203: Studer M, et al. Effect of different antilipidemic agents and diets on mortality: a systematic review. Archives of Internal Medicine, 2005 Apr 11;165(7):725-30.
  • 153: Grech E, et. al. Reperfusion injury after acute myocardial infarction. Brit Med J 1995 310:477-478.
  • 154: Bernier M, et al. Reperfusion-induced arrhythmias and oxygen-derived free radicals. Circulation Res. 1986 58:331-340.
  • 155: Chamiec T, et al. Effects of antioxidant vitamins C and E on signalaveraged electrocardiogram in acute myocardial infarction. Am J Cardiol. 1996 77:277-281.
  • 156: Dzizinskii AA, et al. Effects of antioxidants and membrane protectors on clinical course and hemodynamics of patients of myocardial infarct. Ross Med Zh. 1992 1:32-34.
  • 157: Kramer J, et al. Magnesium-deficiency potentiates free radical production associated with post-ischemic injury to rat hearts: vitamin E affords protection. Free Rad Bio Med. 1994 16:6:713-723.
  • 158: Altura BM. Cardiovascular risk factors and magnesium: relationships to atherosclerosis, ischemic heart disease and hypertension. magnesium and trace elements. Switzerland, S. Karger AG, Basel, 1991-92;10:182-192.
  • 159: Van Leer EM, et al. Dietary calcium, potassium, magnesium and blood pressure in the Netherlands. Internation J Epidem. 1995 24:6:1117-23.
  • 160: Bernier M, et al. Reperfusion-induced arrhythmias and oxygen-derived free radicals. Circulation Res. 1986 58:331-340.
  • 161: Chamiec T, et al. Effects of antioxidant vitamins C and E on signalaveraged electrocardiogram in acute myocardial infarction. Am J Cardiol. 1996 77:277-281.
  • 162: Dzizinskii AA, et al. Effects of antioxidants and membrane protectors on clinical course and hemodynamics of patients of myocardial infarct. Ross Med Zh. 1992 1:32-34.

Ladd McNamara, M.D.

]]> http://www.cholesterolconspiracy.com/episode-16-the-real-and-alternative-way-to-reduce-the-risk-of-death-from-heart-disease-and-stroke-part-3/feed/ 0 Antioxidants,Cholesterol Conspiracy,Essential Fatty Acids,Heart Disease,Ladd McNamara,Minerals,Stroke,Vitamins In this episode Dr. Ladd McNamara discusses vitamins, minerals, antioxidants, and essential fatty acids: a real an alternative way to reduce the risk of death from heart disease and stroke. - Chapter 33: Vitamins, Minerals, Antioxidants, In this episode Dr. Ladd McNamara discusses vitamins, minerals, antioxidants, and essential fatty acids: a real an alternative way to reduce the risk of death from heart disease and stroke. Chapter 33: Vitamins, Minerals, Antioxidants, and Essential Fatty Acids: The Real Way to Reduce the Risk of Death from Heart Disease and Stroke - Part 3 Chapter Excerpts Alpha-Lipoic Acid works in many ways to protect against disease and maintain health. ALA protects LDL cholesterol from oxidation, reduces the inflammatory reaction of the arteries, along with magnesium helps to maintain a health blood pressure. Alpha-Lipoic Acid works together with co-enzyme Q10 in the metabolism of sugar into energy. Olive Oil and Olive Oil Extracts contain polyphenol antioxidants that are in part responsible for the benefits of the Mediterranean diet. Studies have shown those who consume more of these antioxidant compounds have a greatly reduced risk of heart disease and cancer, let alone a prolongation of life. Fish oil supplements (containing DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid) have been shown to decrease the risk of cardiac death greater than the use of statin drugs, ...and without any toxic side-effects. Thus, more evidence of the Cholesterol Conspiracy. In addition to magnesium supplementation, researchers are finding promise in the higher rates of survival after heart attacks when high-dose antioxidants are commenced shortly after such an attack. Diets high in both soluble and insoluble fiber help reduce blood lipid levels, cholesterol, and insulin intolerance. Ladd McNamara, M.D. Chapter References 130: Zhang WJ, Frei B. Alpha-lipoic acid inhibits TNF-alpha-induced NFkappa B activation and adhesion molecule expression in human aortic endothelial cells. FASEB J 2001 Nov;15(13):2423-2432. 131: El Midaoui A, de Champlain J. Prevention of hypertension, insulin resistance, and oxidative stress by alpha-lipoic acid. Hypertension 2002 Feb;39(2):303-307. 132: Takaoka M, et al. Effects of alpha-lipoic acid on deoxycorticos-terone acetate-salt-induced hypertension in rats. Eur J Pharmacol 2001 Jul;20;424(2):121-129. 133: Koufaki M, et al. Novel potent inhibitors of lipid peroxidation with protective effects against reperfusion arrhythmias. J Med Chem 2001 Nov 22;44(24):4300-4303. 134: Gonzalez-Perez O, Gonzalez-Castaneda R, Huerta M, et al. Beneficial effects of -lipoic acid plus vitamin E on neurological deficit, reactive gliosis and neuronal remodeling in the penumbra of the ischemic rat brain. Neuroscience Letters, 2002 March 15, 321(5);1:100-104. 135: Chen C et al. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the carotene and retinal efficacy trial. Cancer Epidimeiol Biomarkers Prev. 2003 Dec;12(12):1410-1416. 136: Upritchard J, Suterhland W, Mann J. Effect of supplementation with tomato juice, vitamin E, and vitamin C oxidation and products of inflammatory activity in type 2 diabetes. Diabetes Care. 2000 Jun;23(6):733-738. 137: Decker E, et al. Inhibition of low-density lipoprotein oxidation by carnosine histidine. J Agric Food Chem 2001 Jan;49(1):511-516. 138: Owen RW, et al. Olive oil consumption and health: the possible role of antioxidants. Lancet Oncol, 2000, Oct., 1:107-12. 139: Visioli F, et al. Antioxidant and other biological activities of phenols from olives and olive oil. Med Res Rev. 2002 Jan;22(1):65-75. 140: Simopoulos Ap. The traditional diet of Greece and cancer. Eur J Cancer Prev. 2004 Jun;13(3):219-30. 141: Visioli F., et al. Low density lipoprotein oxidation is inhibited in vitro by olive oil constituents. Atherosclerosis. 1995 Sep;117(1):25-32. 142: Cullinen K. Olive oil in the treatment of hypercholesterolemia. Med Health R.I. 2006 Mar;89(3):113. 143: Nagyova A, et al. Effects of dietary extra virgin olive oil on serum lipid resistance to oxidation and fatty acid composition in elderly lipidemic patients. The Cholesterol Conspiracy Podcast by Ladd McNamara, M.D. no 16:32 Episode 15: The “Best” Way to Reduce the Risk of Cardiac Death: Part 2 (According to Dr. Ladd McNamara) http://www.cholesterolconspiracy.com/episode-15-the-real-and-alternative-way-to-reduce-the-risk-of-death-from-heart-disease-and-stroke-part-2/ http://www.cholesterolconspiracy.com/episode-15-the-real-and-alternative-way-to-reduce-the-risk-of-death-from-heart-disease-and-stroke-part-2/#comments Tue, 24 Nov 2009 05:51:31 +0000 smp_admin http://www.cholesterolconspiracy.com/?p=74 In this episode Dr. Ladd McNamara discusses vitamins, minerals, antioxidants, and essential fatty acids: a real an alternative way to reduce the risk of death from heart disease and stroke.

  • Chapter 33: Vitamins, Minerals, Antioxidants, and Essential Fatty Acids: The Real Way to Reduce the Risk of Death from Heart Disease and Stroke – Part 2

Chapter Excerpts

Studies using levels of vitamin C, well above 700 mg per day have shown a decreased risk of diseases, including the risk of heart disease.

Ladd McNamara, M.D.

Bioflavanoids such as grape seed extract, resveratrol, & quercetin all have shown remarkable results in reducing the risk of heart disease and cancers. They work synergistically, as well as with other antioxidants to reduce the risk of disease.

L-carnosine may slow down the aging process, and protects the brain, skin, and arteries from damage. Furthermore, L-carnosine helps the heart to contract more effectively through enhancing the use of calcium.

Chapter References

  • 95: Mehra M, et al. Prevention of atherosclerosis. Postgraduate Med. 1995 98:1:175-182.
  • 96: Hoffman RM, et al. Antioxidants and the prevention of coronary heart disease. Arch Int Med. 1995 155:241-244.
  • 97: Morrison H, et al. Serum folate and risk of fatal coronary heart disease. J Am Med Assoc. 1996 275:24:1893-1896.
  • 98: Chasan-Taber L, et al. A prospective study of folate and vitamin B-6 and risk of myocardial infarction in U.S. physicians. J Am Coll Nutri. 1996 15:2:136-143.
  • 99: Levine GN, et al. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 1996 93:6:1107-1113.
  • 100: Gatto LM, et al. Ascorbic acid induces a favorable lipoprotein profile in women. J Am Coll Nutri. 1996 15:2:154-158.
  • 101: Hallfrisch J, et al. High plasma vitamin c associated with high plasma HDL (1) – and HDL (2) cholesterol. Am J Clin Nutri. 1994 60:100-105.
  • 102: Osganian S, Stampfer M, Rimm E, Spiegelman D, et al. Vitamin C and risk of coronary heart disease in women. J Am Coll Cardiol. 2003 42:246-252.
  • 103: Rifici V, Khachadurian A. Dietary supplementation with vitamins C and E inhibits in-vitro oxidation of lipoproteins. J Am Coll Nutri. 1993 12:6:6331-6337.
  • 104: Gaziano J. Antioxidant vitamins and coronary artery disease risk. Am J Med. 1994 97:3A-18S-3A-21S.
  • 105: Lagrue G, et al. A study of the effects of procyanidol oligomers on capillary resistance in hypertension and in certain nephropathies. Sem Hop Paris. 1981 57:1399-1401.
  • 106: Detre A, et al. Studies on vascular permeability in hypertension: action of anthocyanosides. Clin Physiol Biochem. 1986 4:143-149.
  • 107: Meunier MT, et al. Free-radical scavenger activity of procyanidolic oligomers and anthocyanosides with respect to superoxide anion and lipid peroxidation. Plant Medphytother. 1989 4:267-274.
  • 108: Tixier J, et al. Evidence by in vivo and in vitro studies that binding of pycnogenols to elastin affects its rate of degradation by elastases. Biochem Parmacol. 1984 33:3933-3939.
  • 109: Facino R, et al. Free-radical scavenging action and anti-enzyme activities of procyanidines from vitis vinifera; a mechanism for their capillary protective action. Arzneimittel-Forschung Drug Research. 1994 44(1):5:592-601.
  • 110: Dartenuc JY, et al. Capillary resistance in the geriatric: study of a micro-angioprotector. Bordeaux Medicale. 1985 13:903.
  • 111: Kuhnau J. The flavonoids, a class of semi-essential food components: their role in human nutrition. World Rev Nutr Diet. 1976 24:117-191.
  • 112: Gabor M. Pharmacologic effects of flavonoids on blood vessels. Angiologica, 1972 9:355-374.
  • 113: Knekt P, et al. Flavonoid intake and coronary mortality in finland: a cohort study. Brit Med J. 1996 312:478-481.
  • 114: Stephens N, et al. Randomized Controlled Trial of Vitamin E in Patients with Coronary Disease: Cambridge Heart Anti-Oxidant Study (CHAOS). The Lancet. 1996 347:781-786.
  • 115: Niki E, et al. Interaction among vitamin C, vitamin E, and beta carotene. Am J Clin Nutri. 1995 62(suppl):1322S-1326S.
  • 116: Morrison H, et al. Serum folate and risk of fatal coronary heart disease. J Am Med Assoc. 1996 275:24:1893-1896.
  • 117: Carr A, Frei B. Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. Am J Clin Nutr. 1999 69(6):1086-1107.
  • 118: Enstrom J. Counterpoint–vitamin C and mortality. Nutr Today. 1993 28:28-32.
  • 119: Osganian S, Stampfer M, Rimm E, et al. Vitamin C and risk of coronary heart disease in women. J Am Coll Cardiol. 2003 42(2):246-252.
  • 120: Keli S, et al. Dietary flavonoids, antioxidant vitamins, and incidence of stroke: the Zutphen study. Arch Intern Med 1996 Mar 25;156?6):637-642.
  • 121: Duarte J, et al. Antihypertensive effects of the flavonoids quercetin in spontaneously hypertensive rats. Br J Pharmacol 2001 133:117-24.
  • 122: Maron D, Lu G, Cai N, et al. Cholesterol-lowering effect of a theaflavin-enriched green tea extract. A randomized controlled trial. Arch Intern Med. 2003;163:1448-1453.
  • 123: Preston JE, Hipkiss AR, Himsworth DT, et al. Toxic effects of betaamyloid (25-35) on immortalized rat brain endothelial cell: protection by carnosine, homocarnosine and beta-alamine. Neurosci Lett. 1998 242(2):1-0-108.
  • 124: Stadman ER. Protein oxidation and aging. Science. 1992 257(5074):1220-1224.
  • 125: Munch G, Schinzel R, Loske C, et al. Alzheimer’s disease – synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. Journal of Neural Transmission. 1998 105(4-5):439-461.
  • 126: Bierhaus A, Hofmann MA, Ziegler R, et al. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE Concept. Cardiovascular Research. 1998 37(3)586-600.
  • 127: McFarland GA, Holliday R. Retardation of the senescence of cultured human diploid fibroblasts by carnosine. Exp Cell Res. 1994 212(2):167-175.
  • 128: Zaloga GP, Roberts PR, Black KW. Carnosine is a novel peptide modulator of intracellular calcium and contractility in cardiac cells. Am J Physiol 1997 272(1 Pt 2):H462-468.
  • 129: Roberts PR, Zaloga GP. Cardiovascular effects of carnosine. Biochemistry (Mosc) 2000 Jul;65(7):856-861.

Ladd McNamara, M.D.

]]> http://www.cholesterolconspiracy.com/episode-15-the-real-and-alternative-way-to-reduce-the-risk-of-death-from-heart-disease-and-stroke-part-2/feed/ 0 Antioxidants,Bioflavanoids,Cholesterol Conspiracy,Essential Fatty Acids,Heart Disease,Ladd McNamara,Minerals,Stroke,Vitamins In this episode Dr. Ladd McNamara discusses vitamins, minerals, antioxidants, and essential fatty acids: a real an alternative way to reduce the risk of death from heart disease and stroke. - Chapter 33: Vitamins, Minerals, Antioxidants, In this episode Dr. Ladd McNamara discusses vitamins, minerals, antioxidants, and essential fatty acids: a real an alternative way to reduce the risk of death from heart disease and stroke. Chapter 33: Vitamins, Minerals, Antioxidants, and Essential Fatty Acids: The Real Way to Reduce the Risk of Death from Heart Disease and Stroke - Part 2 Chapter Excerpts Studies using levels of vitamin C, well above 700 mg per day have shown a decreased risk of diseases, including the risk of heart disease. Ladd McNamara, M.D. Bioflavanoids such as grape seed extract, resveratrol, & quercetin all have shown remarkable results in reducing the risk of heart disease and cancers. They work synergistically, as well as with other antioxidants to reduce the risk of disease. L-carnosine may slow down the aging process, and protects the brain, skin, and arteries from damage. Furthermore, L-carnosine helps the heart to contract more effectively through enhancing the use of calcium. Chapter References 95: Mehra M, et al. Prevention of atherosclerosis. Postgraduate Med. 1995 98:1:175-182. 96: Hoffman RM, et al. Antioxidants and the prevention of coronary heart disease. Arch Int Med. 1995 155:241-244. 97: Morrison H, et al. Serum folate and risk of fatal coronary heart disease. J Am Med Assoc. 1996 275:24:1893-1896. 98: Chasan-Taber L, et al. A prospective study of folate and vitamin B-6 and risk of myocardial infarction in U.S. physicians. J Am Coll Nutri. 1996 15:2:136-143. 99: Levine GN, et al. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 1996 93:6:1107-1113. 100: Gatto LM, et al. Ascorbic acid induces a favorable lipoprotein profile in women. J Am Coll Nutri. 1996 15:2:154-158. 101: Hallfrisch J, et al. High plasma vitamin c associated with high plasma HDL (1) - and HDL (2) cholesterol. Am J Clin Nutri. 1994 60:100-105. 102: Osganian S, Stampfer M, Rimm E, Spiegelman D, et al. Vitamin C and risk of coronary heart disease in women. J Am Coll Cardiol. 2003 42:246-252. 103: Rifici V, Khachadurian A. Dietary supplementation with vitamins C and E inhibits in-vitro oxidation of lipoproteins. J Am Coll Nutri. 1993 12:6:6331-6337. 104: Gaziano J. Antioxidant vitamins and coronary artery disease risk. Am J Med. 1994 97:3A-18S-3A-21S. 105: Lagrue G, et al. A study of the effects of procyanidol oligomers on capillary resistance in hypertension and in certain nephropathies. Sem Hop Paris. 1981 57:1399-1401. 106: Detre A, et al. Studies on vascular permeability in hypertension: action of anthocyanosides. Clin Physiol Biochem. 1986 4:143-149. 107: Meunier MT, et al. Free-radical scavenger activity of procyanidolic oligomers and anthocyanosides with respect to superoxide anion and lipid peroxidation. Plant Medphytother. 1989 4:267-274. 108: Tixier J, et al. Evidence by in vivo and in vitro studies that binding of pycnogenols to elastin affects its rate of degradation by elastases. Biochem Parmacol. 1984 33:3933-3939. 109: Facino R, et al. Free-radical scavenging action and anti-enzyme activities of procyanidines from vitis vinifera; a mechanism for their capillary protective action. Arzneimittel-Forschung Drug Research. 1994 44(1):5:592-601. 110: Dartenuc JY, et al. Capillary resistance in the geriatric: study of a micro-angioprotector. Bordeaux Medicale. 1985 13:903. 111: Kuhnau J. The flavonoids, a class of semi-essential food components: their role in human nutrition. World Rev Nutr Diet. 1976 24:117-191. 112: Gabor M. Pharmacologic effects of flavonoids on blood vessels. Angiologica, 1972 9:355-374. 113: Knekt P, et al. Flavonoid intake and coronary mortality in finland: a cohort study. Brit Med J. 1996 312:478-481. 114: Stephens N, et al. Randomized Controlled Trial of Vitamin E in Patients with Coronary Disease: Cambridge Heart Anti-Oxidant Study (CHAOS). The Lancet. 1996 347:781-786. 115: Niki E, et al. The Cholesterol Conspiracy Podcast by Ladd McNamara, M.D. no 14:28 Episode 09: Statin Drugs and their Effects (Part One) http://www.cholesterolconspiracy.com/episode-09-statin-drugs-and-their-effects-part-one/ http://www.cholesterolconspiracy.com/episode-09-statin-drugs-and-their-effects-part-one/#comments Wed, 12 Aug 2009 03:32:48 +0000 laddmcnamara http://www.cholesterolconspiracy.com/?p=52 In this episode Dr. McNamara discusses the side effects of Lowering Co-Enzyme Q10 with the usage of Cholesterol-Lowering Statin Drugs.

  • Chapter 20: The Effects of Lowering Co-Enzyme Q10 with Statin Drugs
  • Chapter 21: Statin Drugs May Cause Muscle Weakness & Destruction
  • Chapter 22: Statin Drugs May Cause Heart Disease, Heart Failure, and Death
  • Chapter 23: Statin Drugs May Damage the Liver
  • Chapter 24: Stain Drugs May Damage the Brain and Nerves

Chapter Excerpts

Since all organs and all cells rely on the ubiquitous Co-Q10, the depletion of it by statin drugs causes problems everywhere in the body.

Additionally, Co-Q10 was shown to increase blood levels of vitamin E and significantly increase the levels of protective HDL. As low HDL is a major risk factor for heart disease, increasing it is a definite benefit. Statin drugs were shown not to provide any benefit beyond supplementing with Co-Q10.

Co-Q10 depletion will become more and more of a problem as the pharmaceutical industry encourages doctors to lower cholesterol levels in their patients even more than ever. Is it possible that we are going to see an epidemic of congestive heart disease and cardiomyopathy, as well as cancer, among those taking cholesterol-lowering statin drugs?

So much denial exists within the cholesterol conspiracy that many doctors will not associate common side-effect symptoms and resultant diseases with the use of a statin drug… physicians and patients need to be educated regarding the symptoms of a statin drug are.

Chapter References

  • 35: Cullen D, Bates D, Small S, et al. The incident reporting system does not detect adverse drug events: a problem for quality improvement. Joint Commission Journal on Quality Improvement, Oct. 1995 21(10):541-548.
  • 37: Singh R, Neki N, Kartikey K, et al. Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. Mol Cell Biochem. 2003 Apr; 246(1-2):75-82.
  • 38: Langsjoen P, Langsjoen A. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications. Biofactors. 2003 18(1-4):101-111.
  • 39: Mortensen S. Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone). Clin Investig 1993 71(8 Supp):S116-123 and S140-144.
  • 40: Langsjoen P, Folkers K, Lyson K, et al. Pronounced increase of survival of patients with cardiomyopathy when treated with coenzyme Q10 and conventional therapy. Int J Tissue React 1990 12:163-168.
  • 22: Schwartz G, Olsson A, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. JAMA 2001 285:1711-1718.
  • 41: Gaist D, Jeppesen U, Andersen M, et al. Statins and risk of polyneuropathy: a case-control study. Neurology 2002 May 14; 58(9):1333-1337.
]]> http://www.cholesterolconspiracy.com/episode-09-statin-drugs-and-their-effects-part-one/feed/ 0 Co-Enzyme Q10,Heart Disease,Side Effects,Statin Drugs In this episode Dr. McNamara discusses the side effects of Lowering Co-Enzyme Q10 with the usage of Cholesterol-Lowering Statin Drugs. Chapter 20: The Effects of Lowering Co-Enzyme Q10 with Statin Drugs Chapter 21: Statin Drugs May Cause Muscle We... In this episode Dr. McNamara discusses the side effects of Lowering Co-Enzyme Q10 with the usage of Cholesterol-Lowering Statin Drugs. Chapter 20: The Effects of Lowering Co-Enzyme Q10 with Statin Drugs Chapter 21: Statin Drugs May Cause Muscle Weakness & Destruction Chapter 22: Statin Drugs May Cause Heart Disease, Heart Failure, and Death Chapter 23: Statin Drugs May Damage the Liver Chapter 24: Stain Drugs May Damage the Brain and Nerves Chapter Excerpts Since all organs and all cells rely on the ubiquitous Co-Q10, the depletion of it by statin drugs causes problems everywhere in the body. Additionally, Co-Q10 was shown to increase blood levels of vitamin E and significantly increase the levels of protective HDL. As low HDL is a major risk factor for heart disease, increasing it is a definite benefit. Statin drugs were shown not to provide any benefit beyond supplementing with Co-Q10. Co-Q10 depletion will become more and more of a problem as the pharmaceutical industry encourages doctors to lower cholesterol levels in their patients even more than ever. Is it possible that we are going to see an epidemic of congestive heart disease and cardiomyopathy, as well as cancer, among those taking cholesterol-lowering statin drugs? So much denial exists within the cholesterol conspiracy that many doctors will not associate common side-effect symptoms and resultant diseases with the use of a statin drug... physicians and patients need to be educated regarding the symptoms of a statin drug are. Chapter References 35: Cullen D, Bates D, Small S, et al. The incident reporting system does not detect adverse drug events: a problem for quality improvement. Joint Commission Journal on Quality Improvement, Oct. 1995 21(10):541-548. 37: Singh R, Neki N, Kartikey K, et al. Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. Mol Cell Biochem. 2003 Apr; 246(1-2):75-82. 38: Langsjoen P, Langsjoen A. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications. Biofactors. 2003 18(1-4):101-111. 39: Mortensen S. Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone). Clin Investig 1993 71(8 Supp):S116-123 and S140-144. 40: Langsjoen P, Folkers K, Lyson K, et al. Pronounced increase of survival of patients with cardiomyopathy when treated with coenzyme Q10 and conventional therapy. Int J Tissue React 1990 12:163-168. 22: Schwartz G, Olsson A, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. JAMA 2001 285:1711-1718. 41: Gaist D, Jeppesen U, Andersen M, et al. Statins and risk of polyneuropathy: a case-control study. Neurology 2002 May 14; 58(9):1333-1337. The Cholesterol Conspiracy Podcast by Ladd McNamara, M.D. no 17:08 Episode 07: The Conspiracy to Have Everyone Taking Cholesterol-Lowering Drugs http://www.cholesterolconspiracy.com/episode-07-the-conspiracy-to-have-everyone-taking-cholesterol-lowering-drugs/ http://www.cholesterolconspiracy.com/episode-07-the-conspiracy-to-have-everyone-taking-cholesterol-lowering-drugs/#comments Fri, 24 Jul 2009 01:31:17 +0000 laddmcnamara http://www.cholesterolconspiracy.com/?p=42 In this episode Dr. McNamara discusses the conspiracy to have everyone taking cholesterol-lowering drugs and new recommendations for statin drugs.

  • Chapter 16: Conspiracy to Have Everyone Taking Cholesterol-Lowering Drugs
  • Chapter 17: The Cholesterol-Lowering Statin Drugs and the New Recommendations

Chapter Excerpts

Only 30-40% of people with blocked arteries and heart disease have elevated blood cholesterol levels, and posed the logical question: "How do you explain the other 60 to 70 %?"

The level at which LDL cholesterol is considered normal has continually been influenced by pharmaceutical companies, who pull the financial strings of research grants that keep medical schools and medical organizations running. The lower they can establish the level at which LDL cholesterol is considered normal, the more people automatically become victims of the dreaded disease of "high cholesterol."

The fact is eight of the nine panel members making the new LDL cholesterol recommendations were being paid by the statin-producing pharmaceutical companies. The panelists did not disclose their financial conflict of interest.

Chapter References

  • 17: Rafai N, Ridker P. Inflammatory markers and coronary heart disease. Curr Opin Lipidol 2002 Aug; 13(4):383-389.
  • 18: Albert C, et al. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002 Jun 4; 105 (22):2595-2599.
  • 19: Bermudez E, Ridker P. C-reactive protein, statins, and the primary prevention of atherosclerotic cardiovascular disease. Prev Cardiol 2002 Winter; 5(1):42-46.
  • 20: Blake C, Ridker P. Inflammatory mechanisms in atherosclerosis: from laboratory evidence to clinical application. Ital Heart J 2001 Nov; 2(11):796-800.
  • 21: Grundy SM, Cleeman JI, Bairey Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ; for the Coordinating Committee of the National Cholesterol Education Program. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004 110:227-239.
]]> http://www.cholesterolconspiracy.com/episode-07-the-conspiracy-to-have-everyone-taking-cholesterol-lowering-drugs/feed/ 0 Cholesterol-Lowering Drugs,Heart Disease,Pharmaceutical Industry In this episode Dr. McNamara discusses the conspiracy to have everyone taking cholesterol-lowering drugs and new recommendations for statin drugs. Chapter 16: Conspiracy to Have Everyone Taking Cholesterol-Lowering Drugs Chapter 17: The Cholestero... In this episode Dr. McNamara discusses the conspiracy to have everyone taking cholesterol-lowering drugs and new recommendations for statin drugs. Chapter 16: Conspiracy to Have Everyone Taking Cholesterol-Lowering Drugs Chapter 17: The Cholesterol-Lowering Statin Drugs and the New Recommendations Chapter Excerpts Only 30-40% of people with blocked arteries and heart disease have elevated blood cholesterol levels, and posed the logical question: "How do you explain the other 60 to 70 %?" The level at which LDL cholesterol is considered normal has continually been influenced by pharmaceutical companies, who pull the financial strings of research grants that keep medical schools and medical organizations running. The lower they can establish the level at which LDL cholesterol is considered normal, the more people automatically become victims of the dreaded disease of "high cholesterol." The fact is eight of the nine panel members making the new LDL cholesterol recommendations were being paid by the statin-producing pharmaceutical companies. The panelists did not disclose their financial conflict of interest. Chapter References 17: Rafai N, Ridker P. Inflammatory markers and coronary heart disease. Curr Opin Lipidol 2002 Aug; 13(4):383-389. 18: Albert C, et al. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002 Jun 4; 105 (22):2595-2599. 19: Bermudez E, Ridker P. C-reactive protein, statins, and the primary prevention of atherosclerotic cardiovascular disease. Prev Cardiol 2002 Winter; 5(1):42-46. 20: Blake C, Ridker P. Inflammatory mechanisms in atherosclerosis: from laboratory evidence to clinical application. Ital Heart J 2001 Nov; 2(11):796-800. 21: Grundy SM, Cleeman JI, Bairey Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ; for the Coordinating Committee of the National Cholesterol Education Program. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004 110:227-239. The Cholesterol Conspiracy Podcast by Ladd McNamara, M.D. no 14:09 Episode 04: Homocysteine and Heart Disease http://www.cholesterolconspiracy.com/episode-04-homocysteine-and-heart-disease/ http://www.cholesterolconspiracy.com/episode-04-homocysteine-and-heart-disease/#comments Thu, 02 Jul 2009 03:50:44 +0000 laddmcnamara http://www.cholesterolconspiracy.com/?p=32 In this episode Dr. Ladd McNamara discusses homocysteine blood levels and it’s association with heart disease.

  • Chapter 9: Homocysteine Oxidizes Both LDL Cholesterol and the Arterial Walls
  • Chapter 10: Pharmaceutical Companies Conspire to Hide the Truth
  • Chapter 11: The Discovery of the Association Between Homocysteine and Heart Disease

Chapter Excerpts

Inasmuch as the medical dogma was that high cholesterol caused heart disease, naturally Dr. McCully’s research and findings showing otherwise were blackballed by the pharmaceutical industry.

Homocysteine is second only to cigarette smoking in its oxidative destruction. The combination of oxidized LDL cholesterol and damaged arterial lining (the endothelium) is what causes LDL cholesterol to stick to the arteries, independent of whether the LDL cholesterol level is normal or not.

The Cholesterol Conspiracy includes ignoring one of the major causes of heart disease; thus doctors are unaware of the necessity to test for and reduce homocysteine levels …… Ladd McNamara, M.D.

"I realized immediately that this was a critical case because if this boy had arteriosclerosis, it would prove that no matter what the enzyme defect and no matter what the metabolic pattern, patients with inherited diseases causing homocystinuria also developed arteriosclerosis. Because of this I could attribute formation of the plaques to elevated homocysteine levels."
Kilmer McCully, M.D.

"They told me later they didn’t want to have Harvard or Massachusetts General Hospital associated with my theory because it appeared to contradict the conventional wisdom that cholesterol and fats were the causes of heart disease."
Kilmer McCully, M.D.

Ladd McNamara, M.D. on Dr. McCulley.

Chapter References

  • 10: Haim M, et al. Serum Homocysteine and Long-Term Risk of Myocardial Infarction and Sudden Death in Patients with Coronary Heart Disease. Cardiology. 2006 Jun 6;107(1):52-56.

Ladd McNamara, M.D.

]]> http://www.cholesterolconspiracy.com/episode-04-homocysteine-and-heart-disease/feed/ 0 Cholesterol Conspiracy,Heart Disease,Homocysteine,Ladd McNamara In this episode Dr. Ladd McNamara discusses homocysteine blood levels and it's association with heart disease. - Chapter 9: Homocysteine Oxidizes Both LDL Cholesterol and the Arterial Walls Chapter 10: Pharmaceutical Companies Conspire to Hide the ... In this episode Dr. Ladd McNamara discusses homocysteine blood levels and it's association with heart disease. Chapter 9: Homocysteine Oxidizes Both LDL Cholesterol and the Arterial Walls Chapter 10: Pharmaceutical Companies Conspire to Hide the Truth Chapter 11: The Discovery of the Association Between Homocysteine and Heart Disease Chapter Excerpts Inasmuch as the medical dogma was that high cholesterol caused heart disease, naturally Dr. McCully's research and findings showing otherwise were blackballed by the pharmaceutical industry. Homocysteine is second only to cigarette smoking in its oxidative destruction. The combination of oxidized LDL cholesterol and damaged arterial lining (the endothelium) is what causes LDL cholesterol to stick to the arteries, independent of whether the LDL cholesterol level is normal or not. The Cholesterol Conspiracy includes ignoring one of the major causes of heart disease; thus doctors are unaware of the necessity to test for and reduce homocysteine levels ...... Ladd McNamara, M.D. "I realized immediately that this was a critical case because if this boy had arteriosclerosis, it would prove that no matter what the enzyme defect and no matter what the metabolic pattern, patients with inherited diseases causing homocystinuria also developed arteriosclerosis. Because of this I could attribute formation of the plaques to elevated homocysteine levels." Kilmer McCully, M.D. "They told me later they didn’t want to have Harvard or Massachusetts General Hospital associated with my theory because it appeared to contradict the conventional wisdom that cholesterol and fats were the causes of heart disease." Kilmer McCully, M.D. Ladd McNamara, M.D. on Dr. McCulley. Chapter References 10: Haim M, et al. Serum Homocysteine and Long-Term Risk of Myocardial Infarction and Sudden Death in Patients with Coronary Heart Disease. Cardiology. 2006 Jun 6;107(1):52-56. Ladd McNamara, M.D. The Cholesterol Conspiracy Podcast by Ladd McNamara, M.D. no 17:10 Episode 03: The True Cause of Heart Disease and Stroke http://www.cholesterolconspiracy.com/episode-03-the-true-cause-of-heart-disease-and-stroke/ http://www.cholesterolconspiracy.com/episode-03-the-true-cause-of-heart-disease-and-stroke/#comments Wed, 17 Jun 2009 04:21:17 +0000 laddmcnamara http://www.cholesterolconspiracy.com/?p=28 In this episode Dr. McNamara will discuss the true cause of heart disease and stroke

  • Chapter 8: The True Cause of Heart Disease and Stroke

Chapter Excerpts

LDL cholesterol only becomes “bad” when it is damaged by oxidative free radicals. Only the damaged, or oxidized form of LDL cholesterol sticks to the arterial walls to initiate the formation of plaque.

The push is so strong by pharmaceutical companies to have doctors prescribe statin drugs, that without even a shred of evidence to support the benefits, diabetics with normal cholesterol levels are told to go on statin drugs “ just in case” they might be found to be helpful some day, and the consequences be damned!

Chapter References

  • 2: Schroecksnadel K, et al. Crucial role of interferon-gamma and stimulated macrophages in cardiovascular disease. Curr Vasc Pharmacol. 2006 Jul;4(3):205-13.
  • 3: Gibelin P, et al. Prognostic value of homocysteinemia in patients with congestive heart failure. Clin Chem Lab Med. 2006;44(7):813-6.
  • 4: Van Oijen MG, et al. Hyperhomocysteinaemia and Vitamin B12 Deficiency: The Long-Term Effects in Cardiovascular Disease. Cardiology. 2006 Jun 6;107(1):57-62 [Epub ahead of print].
  • 5: Haim M, et al. Serum Homocysteine and Long-Term Risk of Myocardial Infarction and Sudden Death in Patients with Coronary Heart Disease. Cardiology. 2006 Jun 6;107(1):52-56.
  • 6: Laaksonen R, et al. High oxidized LDL and elevated plasma homocysteine contribute to the early reduction of myocardial flow reserve in healthy adults. Eur J Clin Invest. 2002 Nov;32(11):795-802.
  • 7: Troughton JA, et al. Homocysteine and coronary heart disease risk in the PRIME study. Atherosclerosis. 2006 Jun 13; [Epub ahead of print].
  • 8: Tsimikas, S, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005 Jul 7;353(1):9-11.
  • 9: Anselmi M, et al. Plasma levels of oxidized-low-density lipoproteins are higher in patients with unstable angina and correlated with angiographic coronary complex plaques. Atherosclerosis. 2006 Mar;185(1):114-20.
]]> http://www.cholesterolconspiracy.com/episode-03-the-true-cause-of-heart-disease-and-stroke/feed/ 0 Heart Disease,LDL Cholesterol,Statin Drugs,Stroke In this episode Dr. McNamara will discuss the true cause of heart disease and stroke Chapter 8: The True Cause of Heart Disease and Stroke Chapter Excerpts LDL cholesterol only becomes “bad” when it is damaged by oxidative free radicals. In this episode Dr. McNamara will discuss the true cause of heart disease and stroke Chapter 8: The True Cause of Heart Disease and Stroke Chapter Excerpts LDL cholesterol only becomes “bad” when it is damaged by oxidative free radicals. Only the damaged, or oxidized form of LDL cholesterol sticks to the arterial walls to initiate the formation of plaque. The push is so strong by pharmaceutical companies to have doctors prescribe statin drugs, that without even a shred of evidence to support the benefits, diabetics with normal cholesterol levels are told to go on statin drugs “ just in case” they might be found to be helpful some day, and the consequences be damned! Chapter References 2: Schroecksnadel K, et al. Crucial role of interferon-gamma and stimulated macrophages in cardiovascular disease. Curr Vasc Pharmacol. 2006 Jul;4(3):205-13. 3: Gibelin P, et al. Prognostic value of homocysteinemia in patients with congestive heart failure. Clin Chem Lab Med. 2006;44(7):813-6. 4: Van Oijen MG, et al. Hyperhomocysteinaemia and Vitamin B12 Deficiency: The Long-Term Effects in Cardiovascular Disease. Cardiology. 2006 Jun 6;107(1):57-62 [Epub ahead of print]. 5: Haim M, et al. Serum Homocysteine and Long-Term Risk of Myocardial Infarction and Sudden Death in Patients with Coronary Heart Disease. Cardiology. 2006 Jun 6;107(1):52-56. 6: Laaksonen R, et al. High oxidized LDL and elevated plasma homocysteine contribute to the early reduction of myocardial flow reserve in healthy adults. Eur J Clin Invest. 2002 Nov;32(11):795-802. 7: Troughton JA, et al. Homocysteine and coronary heart disease risk in the PRIME study. Atherosclerosis. 2006 Jun 13; [Epub ahead of print]. 8: Tsimikas, S, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005 Jul 7;353(1):9-11. 9: Anselmi M, et al. Plasma levels of oxidized-low-density lipoproteins are higher in patients with unstable angina and correlated with angiographic coronary complex plaques. Atherosclerosis. 2006 Mar;185(1):114-20. The Cholesterol Conspiracy Podcast by Ladd McNamara, M.D. no 13:12 Episode 02: Medical Education and Heart Disease http://www.cholesterolconspiracy.com/episode-02-medical-education-and-heart-disease/ http://www.cholesterolconspiracy.com/episode-02-medical-education-and-heart-disease/#comments Wed, 10 Jun 2009 04:20:08 +0000 laddmcnamara http://www.cholesterolconspiracy.com/?p=25 In this episode Dr. McNamara discusses how the Pharmaceutical Industry influences medical education and the myth that high cholesterol is the primary cause of heart disease.

  • Chapter 5: How the Pharmaceutical Industry Influences Medical Education
  • Chapter 6: The Myth that High Cholesterol Causes Heart Disease
  • Chapter 7: The Number One Cause of Death in the United States

Chapter Excerpts

It was only about ten years ago that the Surgeon General declared that 68% of all disease is caused by diet.
That would make a poor diet the number one cause of ill health in the United States, not the omission of prescription drugs.
A poor diet is defined as a lack of vitamins, minerals, antioxidants, essential fatty acids.

As there was more money to be made from pharmaceutical development, the campaign to produce cholesterol-lowering drugs kicked into high gear, despite the lack of evidence showing that lowering cholesterol reduced the risk of death from heart disease.

]]> http://www.cholesterolconspiracy.com/episode-02-medical-education-and-heart-disease/feed/ 0 Heart Disease,Medical Education In this episode Dr. McNamara discusses how the Pharmaceutical Industry influences medical education and the myth that high cholesterol is the primary cause of heart disease. Chapter 5: How the Pharmaceutical Industry Influences Medical Education C... In this episode Dr. McNamara discusses how the Pharmaceutical Industry influences medical education and the myth that high cholesterol is the primary cause of heart disease. Chapter 5: How the Pharmaceutical Industry Influences Medical Education Chapter 6: The Myth that High Cholesterol Causes Heart Disease Chapter 7: The Number One Cause of Death in the United States Chapter Excerpts It was only about ten years ago that the Surgeon General declared that 68% of all disease is caused by diet. That would make a poor diet the number one cause of ill health in the United States, not the omission of prescription drugs. A poor diet is defined as a lack of vitamins, minerals, antioxidants, essential fatty acids. As there was more money to be made from pharmaceutical development, the campaign to produce cholesterol-lowering drugs kicked into high gear, despite the lack of evidence showing that lowering cholesterol reduced the risk of death from heart disease. The Cholesterol Conspiracy Podcast by Ladd McNamara, M.D. no 15:20